TRex Bio, Inc. announced its IPO, offering 8.33 million shares at $14 each, raising approximately $116.7 million.
Quiver AI Summary
TRex Bio, Inc. has announced the pricing of its initial public offering (IPO) of 8,333,334 shares of common stock at $14.00 per share, aiming to raise approximately $116.7 million before expenses. The shares will begin trading on the Nasdaq Global Select Market under the ticker symbol "TRXB" on October 9, 2026, with the offering expected to close on October 13, 2026, pending the usual closing conditions. Additionally, TRexBio has granted underwriters a 30-day option to purchase up to an additional 1,250,000 shares. The company focuses on developing immunoregulatory medicines through its Deep Biology Platform, which aims to address autoimmune and inflammatory diseases by restoring immune balance. The registration statement for this offering has been filed with the SEC and is now effective.
Potential Positives
- TRex Bio successfully priced its initial public offering (IPO) at $14.00 per share, raising approximately $116.7 million in gross proceeds, which can significantly strengthen the company's financial position.
- The company is poised to begin trading on the Nasdaq Global Select Market under the ticker symbol “TRXB,” which can enhance its visibility and credibility in the market.
- TRexBio's IPO allows for the potential further development of its innovative therapies targeting autoimmune and inflammatory diseases, addressing significant unmet medical needs.
- The involvement of reputable banks as lead book-running managers indicates strong institutional support and confidence in TRexBio's business prospects.
Potential Negatives
- The press release highlights the uncertainties surrounding the completion of the initial public offering, which may deter potential investors.
- The necessity to rely on customary closing conditions and market conditions introduces additional risk factors that could affect the IPO.
- There is no guarantee that the pricing of $14.00 per share accurately reflects the company's long-term value, which could lead to volatility post-IPO.
FAQ
What is TRex Bio's IPO price per share?
TRex Bio's initial public offering price is set at $14.00 per share.
When will TRex Bio's stock begin trading?
TRex Bio’s common stock is expected to start trading on October 9, 2026.
How much is TRex Bio aiming to raise through the IPO?
The gross proceeds from the IPO are expected to be approximately $116.7 million.
Who are the underwriters for TRex Bio's IPO?
J.P. Morgan, Evercore ISI, Cantor, Stifel, and Wedbush PacGrow are the underwriters for the offering.
What does TRex Bio specialize in?
TRex Bio focuses on tissue Treg biology to develop immunoregulatory medicines for autoimmune and inflammatory diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $116.7 million. TRexBio’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 9, 2026, under the ticker symbol “TRXB”. The offering is expected to close on October 13, 2026, subject to the satisfaction of customary closing conditions. In addition, TRexBio has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager for the offering.
A registration statement (File No. 333-299018) relating to the shares being sold in the offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on October 8, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, Attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; and Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at [email protected] or by telephone at (888) 474-0200.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About TRexBio
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio’s Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the completion, timing, and size of the initial public offering and the commencement of trading on the Nasdaq Global Select Market. Each forward-looking statement is subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described or at all. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of TRexBio, including, without limitation, market conditions, failure of customary closing conditions, and the factors discussed in the “Risk Factors” section of the prospectus that forms a part of the registration statement, in the form last filed with the SEC. These forward-looking statements speak only as of the date of this press release and TRexBio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
